PASCAL CAISEY

About PASCAL CAISEY

Pascal Caisey currently holds a key leadership role at GENFIT, the French biopharmaceutical company focused on liver and metabolic diseases. He joined GENFIT in September 2019 as Executive Vice President of Commercial Development, was promoted to Chief Commercial Officer in January 2021, and was appointed Chief Operating Officer in March 2022. This career path reflects the confidence placed in his ability to help shape the commercial and operational backbone of a biopharma company moving toward late-stage development and market readiness. Before joining GENFIT, Pascal Caisey built a broad career in the pharmaceutical industry, holding positions at GSK, Bristol Myers Squibb, Pfizer, and Schering-Plough. He later took on senior responsibilities at Boehringer Ingelheim, where he oversaw the commercial launch of empagliflozin in Europe as European Business Manager. That experience gave him hands-on expertise in product launches, market access, multi-country commercial strategy, and execution across European markets. His academic and professional background further strengthens his profile. Pascal Caisey is a registered nurse and holds an MBA from HEC Paris, a combination that brings together clinical understanding, patient focus, and business leadership. Public sources also note his Executive MBA studies at HEC Paris. This blend of healthcare and management experience is particularly valuable for a company like GENFIT, whose long-term success depends on scientific innovation, disciplined corporate governance, and the ability to prepare and execute future commercialization plans. At GENFIT, Pascal Caisey has helped support the company’s transition from a research-centric organization toward a more integrated operating model capable of coordinating development, commercial preparation, and execution. His inclusion in the Executive Committee coincided with the strengthening of GENFIT’s operational governance. In a demanding biopharmaceutical environment, his expertise is especially relevant for decisions involving market entry strategy, resource allocation, and alignment between research and business priorities, all of which are essential to long-term value creation.